Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways

Signaling Pathways

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Targets for  Signaling Pathways

Products for  Signaling Pathways

  1. Cat.No. Product Name Information
  2. GC14729 (R)-Crizotinib A c-MET and ALK receptor tyrosine kinase inhibitor (R)-Crizotinib Chemical Structure
  3. GC62738 (R)-eIF4A3-IN-2 (R)-eIF4A3-IN-2 is a less active enantiomer of eIF4A3-IN-2. (R)-eIF4A3-IN-2 Chemical Structure
  4. GC69812 (R)-Elexacaftor

    (R)-Elexacaftor is the enantiomer of Elexacaftor (Compound 1) and comes from Compound 37 in patent WO2018107100A1. It is a corrector of cystic fibrosis transmembrane conductance regulator (CFTR), with an EC50 value of 0.29 uM for CFTR dF508.

     (R)-Elexacaftor Chemical Structure
  5. GC67857 (R)-Elsubrutinib (R)-Elsubrutinib Chemical Structure
  6. GC64179 (R)-Fangchinoline (R)-Fangchinoline (Thalrugosine), a alkaloids from genus Stephania，exhibits antimicrobial and hypotensive activity. (R)-Fangchinoline Chemical Structure
  7. GC65384 (R)-FL118 (R)-FL118 (10,11-(Methylenedioxy)-20(R)-camptothecin) is the R-enantiomer of FL118. (R)-FL118 shows anticancer activity. (R)-FL118 Chemical Structure
  8. GC62739 (R)-Funapide (R)-Funapide ((R)-TV 45070) is the less active R-enantiomer of Funapide. (R)-Funapide Chemical Structure
  9. GC64210 (R)-GSK-3685032 (R)-GSK-3685032 is the R-enantiomer of GSK-3685032. GSK-3685032 is a non-time-dependent, noncovalently, first-in-class reversible DNMT1-selective inhibitor, with an IC50 of 0.036 μM. GSK-3685032 induces robust loss of DNA methylation, transcriptional activation, and cancer cell growth inhibition. (R)-GSK-3685032 Chemical Structure
  10. GC52290 (R)-HTS-3 An inhibitor of LPCAT3 (R)-HTS-3 Chemical Structure
  11. GC49066 (R)-Hydroxychloroquine (sulfate) An isomer of hydroxychloroquine (R)-Hydroxychloroquine (sulfate) Chemical Structure
  12. GC65373 (R)-IL-17 modulator 4 (R)-IL-17 modulator 4 is the R-configure of IL-17 modulator 4. (R)-IL-17 modulator 4 Chemical Structure
  13. GC67864 (R)-Irsenontrine (R)-Irsenontrine Chemical Structure
  14. GC61847 (R)-Lanicemine (R)-Lanicemine ((R)-AZD6765) is the less active R-enantiomer of Lanicemine. (R)-Lanicemine Chemical Structure
  15. GC66419 (R)-Lercanidipine-d3 hydrochloride (R)-lercanidipine D3 (hydrochloride) is a deuterium labeled (R)-Lercanidipine hydrochloride. (R)-Lercanidipine D3 (hydrochloride), the R-enantiomer of Lercanidipine, is a calcium channel blocker. (R)-Lercanidipine-d3 hydrochloride Chemical Structure
  16. GC62740 (R)-M8891 (R)-M8891 (compound R-9) is a less active isomer of M8891. (R)-M8891 Chemical Structure
  17. GC67937 (R)-Mirtazapine (R)-Mirtazapine Chemical Structure
  18. GC61858 (R)-MLN-4760 (R)-MLN-4760, the R-enantiomer of MLN-4760, is an ACE2 inhibitor, with an IC50 of 8.4 μM. (R)-MLN-4760 Chemical Structure
  19. GC68475 (R)-Nicardipine (R)-Nicardipine Chemical Structure
  20. GC67767 (R)-Olacaftor (R)-Olacaftor Chemical Structure
  21. GC64366 (R)-ONO-2952 (R)-ONO-2952 is a R-enantiomer of ONO-2952. (R)-ONO-2952 Chemical Structure
  22. GC49253 (R)-P7C3-Ome An analog of P7C3-A20 (R)-P7C3-Ome Chemical Structure
  23. GC67717 (R)-PF-04991532 (R)-PF-04991532 Chemical Structure
  24. GC62741 (R)-PF-06256142 (R)-PF-06256142 is the R enantiomer of PF-06256142 with low active. (R)-PF-06256142 Chemical Structure
  25. GC62742 (R)-Pirtobrutinib (R)-Pirtobrutinib ((R)-LOXO-305) is a less active enantiomer of Pirtobrutinib. (R)-Pirtobrutinib Chemical Structure
  26. GC62513 (R)-Posenacaftor sodium (R)-Posenacaftor (R)-PTI-801) sodium is the R enantiomer of Posenacaftor. (R)-Posenacaftor sodium Chemical Structure
  27. GC68408 (R)-Praziquantel-d11 (R)-Praziquantel-d11 Chemical Structure
  28. GC68383 (R)-Preclamol (R)-Preclamol Chemical Structure
  29. GC63802 (R)-PS210 (R)-PS210, the R enantiomer of PS210 (compound 4h-eutomer), is a substrate-selective allosteric activator of PDK1 with an AC50 value of 1.8 μM. (R)-PS210 targets to the PIF-binding pocket of?PDK1. PIF: The protein kinase C-related kinase 2 (PRK2)-interacting fragment. (R)-PS210 Chemical Structure
  30. GC65591 (R)-RP-6306 (R)-RP-6306 (183) can be used for the research of Myt1 mediated diseases and kinds of cancer for slowing the progression of cancer. (R)-RP-6306 Chemical Structure
  31. GC69839 (R)-Tegoprazan

    (R)-Tegoprazan ((R)-CJ-12420; example 3) is a benzimidazole derivative and an effective inhibitor of gastric H+/K+-ATPase. Its IC50 for canine kidney Na+/K+-ATPase is 98 nM. (R)-Tegoprazan has potential in the research of gastrointestinal diseases.

     (R)-Tegoprazan Chemical Structure
  32. GC69847 (R)-VT104

    (R)-VT104 is the R-enantiomer of VT104. The IC50 value of (R)-VT104 for firefly luciferase is 0.1-1 μμ. VT104 is an orally active pan-TEAD deacetylase inhibitor.

     (R)-VT104 Chemical Structure
  33. GC65884 (R,1R)-Tenofovir amibufenamide (R,1R)-Tenofovir amibufenamide ((R,1R)-HS-10234) can be used for the purifying a tenofovir prodrug. Tynofovir (tenofovir) is a nucleoside acids reverse transcriptase inhibitors. (R,1R)-Tenofovir amibufenamide Chemical Structure
  34. GC63983 (R,R)-BAY-Y 3118 (R,R)-BAY-Y 3118 is the R-enantiomer of BAY-Y 3118. (R,R)-BAY-Y 3118 Chemical Structure
  35. GC62588 (R,R)-CXCR2-IN-2 (R,R)-CXCR2-IN-2, diastereoisomer of CXCR2-IN-2 (compound 68), is a brain penetrant CXCR2 antagonist with a pIC50 of 9 and 6.8 in the Tango assay and d in the HWB Gro-α induced CD11b expression assay, respectively. (R,R)-CXCR2-IN-2 Chemical Structure
  36. GC14145 (R,R)-Formoterol β2-selective adrenergic agonist (R,R)-Formoterol Chemical Structure
  37. GC69836 (R,R)-VVD-118313

    (R,R)-VVD-118313 is an isomer of VVD-118313. VVD-118313 is a selective JAK1 inhibitor that can block JAK1-dependent phosphorylation and cytokine signaling. VVD-118313 can be used for cancer research.

     (R,R)-VVD-118313 Chemical Structure
  38. GC52185 (R,S)-Anatabine-d4 (R,S)-Anatabine-d4 Chemical Structure
  39. GC69837 (R/S)-Alicaforsen

    (R/S)-Alicaforsen is the racemic form of Alicaforsen, which consists of both R and S configurations. Alicaforsen is a 20-base length antisense oligonucleotide that inhibits the production of ICAM-1, an important adhesion molecule involved in the migration and transport process of white blood cells to inflammatory sites.

     (R/S)-Alicaforsen Chemical Structure
  40. GC63452 (Rac)-5-Hydroxymethyl Tolterodine (Rac)-5-Hydroxymethyl Tolterodine ((Rac)-Desfesoterodine), an active metabolite of Tolterodine, is a mAChR antagonist (Ki values of 2.3 nM, 2 nM, 2.5 nM, 2.8 nM, and 2.9 nM for M1, M2, M3, M4, and M5 receptors, respectively). (Rac)-5-Hydroxymethyl Tolterodine Chemical Structure
  41. GC61548 (Rac)-5-Keto Fluvastatin (Rac)-5-Keto Fluvastatin (3-Hydroxy-5-Keto Fluvastatin) is an impurity of Fluvastatin (XU 62320). (Rac)-5-Keto Fluvastatin Chemical Structure
  42. GC61488 (Rac)-Acolbifene (Rac)-Acolbifene (EM-343; (Rac)-EM-652) is the racemic form of EM652 (estrogen receptor?antagonist), has anti-estrogenic and estrogenic activities. (Rac)-Acolbifene (EM-343; (Rac)-EM-652) contains a piperidine ring, shows good pharmacological profile,relative binding affinity (RBA)=380. (Rac)-Acolbifene Chemical Structure
  43. GC69794 (Rac)-Arnebin 1

    (Rac)-Arnebin 1 is the racemic form of β,β-Dimethylacrylalkannin and/or β,β-Dimethylacrylshikonin. These compounds are naphthoquinones isolated from plants in the Lithospermum genus, with β,β-Dimethylacrylshikonin exhibiting anti-tumor activity.

     (Rac)-Arnebin 1 Chemical Structure
  44. GC68414 (Rac)-Atropine-d3 (Rac)-Atropine-d3 Chemical Structure
  45. GC69795 (Rac)-BIO8898

    (Rac)-BIO8898 is a CD40-CD154 co-stimulatory interaction inhibitor. (Rac)-BIO8898 inhibits the binding of CD154 to CD40-Ig, with an IC50 of 25 μM.

     (Rac)-BIO8898 Chemical Structure
  46. GC65477 (Rac)-CFT7455 (Rac)-CFT7455 is a zinc finger transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) degrader, acting via the ubiquitin proteasome pathway, with a GI50 of 0.05 nM for NCIH929.1 cells. (Rac)-CFT7455 is the racemic isomer of CFT7455 which is a IKZF1/IKZF3 degrader with anticancer activity. (Rac)-CFT7455 Chemical Structure
  47. GC67993 (Rac)-Cotinine-d4 (Rac)-Cotinine-d4 Chemical Structure
  48. GC63511 (Rac)-CP-601927 hydrochloride (Rac)-CP-601927 hydrochloride is the racemate of CP-601927. (Rac)-CP-601927 hydrochloride Chemical Structure
  49. GC64481 (rac)-Dobutamine-d4 hydrochloride (rac)-Dobutamine-d4 hydrochloride Chemical Structure
  50. GC62642 (rac)-Dobutamine-d6 hydrochloride (rac)-Dobutamine-d6 hydrochloride Chemical Structure
  51. GC62743 (Rac)-EC5026 (Rac)-EC5026 ((Rac)-BPN-19186) is a potent piperidine inhibitor of soluble epoxide hydrolase (sEH) extracted from patent WO2019156991A1, page 39, has a Ki of 0.06 nM. (Rac)-EC5026 Chemical Structure
  52. GC69796 (Rac)-Etavopivat

    (Rac)-Etavopivat ((Rac)-FT-4202) is an isomer of Etavopivat. Etavopivat is an orally active activator of red blood cell pyruvate kinase-R (PKR), which can be used for research on sickle cell disease and other hemoglobin disorders.

     (Rac)-Etavopivat Chemical Structure
  53. GC62332 (Rac)-Finerenone (Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. (Rac)-Finerenone Chemical Structure
  54. GC62528 (Rac)-Hesperetin (Rac)-Hesperetin is the racemate of Hesperetin. (Rac)-Hesperetin Chemical Structure
  55. GC61750 (Rac)-Indoximod (Rac)-Indoximod (1-Methyl-DL-tryptophan) is an indoleamine 2,3-dioxygenase (IDO) inhibitor. (Rac)-Indoximod Chemical Structure
  56. GC61446 (Rac)-Lanicemine (Rac)-Lanicemine ((Rac)-AZD6765) is the racemate of Lanicemine. (Rac)-Lanicemine Chemical Structure
  57. GC63632 (Rac)-Lorcaserin (Rac)-Lorcaserin Chemical Structure
  58. GC63382 (Rac)-Lorcaserin hydrochloride (Rac)-Lorcaserin hydrochloride Chemical Structure
  59. GC64069 (Rac)-Lys-SMCC-DM1 (Rac)-Lys-SMCC-DM1 ((Rac)-Lys-Nε-MCC-DM1) is the racemate of Lys-SMCC-DM1. Lys-SMCC-DM1 is a linker-payload component that has the potential to inhibit tubulin polymerization. Lys-SMCC-DM1 is the active metabolite of T-DM1. (Rac)-Lys-SMCC-DM1 Chemical Structure
  60. GC61873 (Rac)-MEM 1003 (Rac)-MEM 1003 is the racemate of MEM 1003. (Rac)-MEM 1003 Chemical Structure
  61. GC64490 (Rac)-MGV354 (Rac)-MGV354 is the racemate of MGV354. (Rac)-MGV354 Chemical Structure
  62. GC63410 (Rac)-MRI-1867 (Rac)-MRI-1867 ((Rac)-MRI-1867, compound 6b) is a cannabinoid receptor type 1 (CB1R)/iNOS antagonist, with a Ki of 5.7 nM for CB1R. (Rac)-MRI-1867 Chemical Structure
  63. GC62228 (rac)-Nebivolol-d4 (Rac)-Nebivolol-d4 ((Rac)-R 065824-d4) is a labelled racemic Nebivolol. (rac)-Nebivolol-d4 Chemical Structure
  64. GC62744 (Rac)-OSMI-1 (Rac)-OSMI-1 is the racemate of OSMI-1. (Rac)-OSMI-1 Chemical Structure
  65. GC62745 (Rac)-PF-06256142 (Rac)-PF-06256142 is the less effective enantiomer of PF-06256142. (Rac)-PF-06256142 Chemical Structure
  66. GC66334 (Rac)-PF-184 hydrate (Rac)-PF-184 hydrate is a potent inhibitory factor-κB kinase 2 (IKK-2) inhibitor with an IC50 of 37 nM. (Rac)-PF-184 hydrate has anti-inflammatory effects. (Rac)-PF-184 hydrate Chemical Structure
  67. GC63292 (rac)-PF-998425 (Rac)-PF-998425 is a potent, selective, nonsteroidal androgen receptor (AR) antagonist. (rac)-PF-998425 Chemical Structure
  68. GC64123 (Rac)-RP-6306 (Rac)-RP-6306 (compound 181) is a potent Myt1 inhibitor with an IC50 of <10 nM. (Rac)-RP-6306 (compound 181) has anticancer effects. (Rac)-RP-6306 Chemical Structure
  69. GC69797 (Rac)-SHIN2

    (Rac)-SHIN2 is a serine hydroxymethyltransferase (SHMT) inhibitor with a 1,4-dihydropyran[2,3-c]pyrazole structure. It is involved in folate or one-carbon metabolism pathways and prevents viral infections. SHMT1 and SHMT2 are cytosolic and/or mitochondrial isoforms of serine hydroxymethyltransferase respectively.

     (Rac)-SHIN2 Chemical Structure
  70. GC69798 (Rac)-SNC80

    (Rac)-SNC80 is the racemic form of SNC80. SNC80 (NIH 10815) is an effective and highly selective non-peptide delta-opioid receptor agonist with a Ki of 1.78 nM and IC50 of 2.73 nM. SNC80 has anti-nociceptive, anti-hyperalgesic, and antidepressant-like effects, and can be used in research on various types of headaches.

     (Rac)-SNC80 Chemical Structure
  71. GC64905 (Rac)-Upacicalcet (Rac)-Upacicalcet is the racemate of Upacicalcet. (Rac)-Upacicalcet Chemical Structure
  72. GC69799 (Rac)-ZLc-002

    (Rac)-ZLc-002 is an inhibitor that interacts with the binding protein between nNOS and nitric oxide synthase 1 (NOS1AP). It inhibits inflammatory pain and chemotherapy-induced neuropathic pain, and synergistically reduces tumor cell viability with Paclitaxel.

     (Rac)-ZLc-002 Chemical Structure
  73. GC62746 (RS)-AMPA monohydrate (RS)-AMPA ((±)-AMPA) monohydrate is a glutamate analogue and a potent and selective excitatory neurotransmitter L-glutamic acid agonist. (RS)-AMPA monohydrate Chemical Structure
  74. GC64804 (S)-(+)-Ibuprofen D3 (S)-(+)-Ibuprofen D3 ((S)-Ibuprofen D3) is a deuterium labeled (S)-(+)-Ibuprofen. (S)-(+)-Ibuprofen D3 Chemical Structure
  75. GC25002 (S)-(-)-α-Methylbenzylamine (S)-(-)-α-Methylbenzylamine is a chiral auxiliary in the enantiodivergent synthesis of simple isoquinoline alkaloids. (S)-(-)-α-Methylbenzylamine Chemical Structure
  76. GC62747 (S)-(-)-Citronellal (S)-(-)-Citronellal Chemical Structure
  77. GC63321 (S)-(-)-Felodipine-d5 (S)-(-)-Felodipine-d5 Chemical Structure
  78. GC64735 (S)-(-)-Levamisole (S)-(-)-Levamisole (Levamisole), an anthelmintic agent with immunomodulatory properties. (S)-(-)-Levamisole Chemical Structure
  79. GC66076 (S)-1-Benzylpyrrolidin-3-ol (S)-1-Benzylpyrrolidin-3-ol (Compound 14) can be used to synthesis impurities of the anti-hypertensive drug Barnidipine hydrochloride (HY-107322). (S)-1-Benzylpyrrolidin-3-ol Chemical Structure
  80. GC62748 (S)-2-Amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid dihydrate (S)-2-Amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid dihydrate is an endogenous metabolite. (S)-2-Amino-3-(4-hydroxy-3,5-diiodophenyl)propanoic acid dihydrate Chemical Structure
  81. GC64746 (S)-2-Hydroxybutanoic acid (S)-2-Hydroxybutanoic acid is the S-enantiomer of?2-Hydroxybutanoic acid. (S)-2-Hydroxybutanoic acid Chemical Structure
  82. GC64473 (S)-3,4-Dihydroxybutyric acid lithium hydrate (S)-3,4-Dihydroxybutyric acid (lithium hydrate) is a normal human urinary metabolite that is excreted in increased concentration in patients with succinic semialdehyde dehydrogenase (SSADH) deficiency. (S)-3,4-Dihydroxybutyric acid lithium hydrate Chemical Structure
  83. GC62749 (S)-3-Hydroxy-2-(Phosphonooxy)Propanoic Acid (S)-3-Hydroxy-2-(Phosphonooxy)Propanoic Acid is an endogenous metabolite. (S)-3-Hydroxy-2-(Phosphonooxy)Propanoic Acid Chemical Structure
  84. GC49028 (S)-3-Thienylglycine A thienyl-containing amino acid (S)-3-Thienylglycine Chemical Structure
  85. GC52192 (S)-4'-nitro-Blebbistatin (S)-4'-nitro-Blebbistatin is a non-cytotoxic, photostable, fluorescent and specific Myosin II inhibitor, usd in the study of the specific role of myosin II in physiological, developmental, and cell biological studies. (S)-4'-nitro-Blebbistatin Chemical Structure
  86. GC63655 (S)-Amisulpride (S)-Amisulpride (Esamisulpride) is a potent dopamine D2/D3 receptor antagonist. (S)-Amisulpride Chemical Structure
  87. GC64594 (S)-Baxdrostat (S)-Baxdrostat is the S-enantiomer of Baxdrostat. (S)-Baxdrostat Chemical Structure
  88. GC48719 (S)-Canadine (S)-Canadine is an alkaloid and intermediate in the biosynthesis of berberine with insecticidal activity. (S)-Canadine Chemical Structure
  89. GC62750 (S)-Enzaplatovir (S)-Enzaplatovir ((S)-BTA-C585) is the S-enantiomer of Enzaplatovir. (S)-Enzaplatovir shows antiviral activities with an EC50 of 56 nM for respiratory syncytial viral (RSV) (patent WO2011094823A1 compound 77). (S)-Enzaplatovir Chemical Structure
  90. GC49520 (S)-Equol

    An estrogen receptor β agonist

     (S)-Equol Chemical Structure
  91. GC63526 (S)-ErSO (S)-ErSO is the dextrorotatory enantiomer of ErSO. (S)-ErSO is inactive in MCF-7 cells (from patent WO2020009958A1, compound (s)-105). (S)-ErSO Chemical Structure
  92. GC65877 (S)-GFB-12811 (S)-GFB-12811 (compound 596) is a potent and selective CDK5 inhibitor, with an IC50 value less than 10 nM. (S)-GFB-12811 can be used in the research of cell cycle progression, neuronal development, tumorigenesis. (S)-GFB-12811 Chemical Structure
  93. GC62751 (S)-Higenamine hydrobromide (S)-Higenamine ((S)-Norcoclaurine) hydrobromide, a S-enantiomer of Higenamine, is the entry compound in benzylisoquinoline alkaloid biosynthesis. (S)-Higenamine hydrobromide Chemical Structure
  94. GC49067 (S)-Hydroxychloroquine (sulfate) An isomer of hydroxychloroquine (S)-Hydroxychloroquine (sulfate) Chemical Structure
  95. GC69890 (S)-Imlunestrant tosylate

    (S)-Imlunestrant tosylate ((S)-LY-3484356) is the (S)-enantiomer of Imlunestrant. It can be used for cancer research.

     (S)-Imlunestrant tosylate Chemical Structure
  96. GC69891 (S)-Indoximod-d3

    (S)-Indoximod-d3 is the deuterated form of (S)-Indoximod. (S)-Indoximod (1-Methyl-L-tryptophan) is an inhibitor of indoleamine 2,3-dioxygenase (IDO). (S)-Indoximod can be used for cancer research.

     (S)-Indoximod-d3 Chemical Structure
  97. GC69904 (S)-JDQ-443

    (S)-JDQ-443 is an isomer of JDQ-443. JDQ-443 is an orally effective and selective covalent KRAS G12C inhibitor. JDQ-443 has anti-tumor activity.

     (S)-JDQ-443 Chemical Structure
  98. GC65997 (S)-LY3177833 hydrate (S)-LY3177833 ((S)-Example 2) hydrate is an orally active CDC7 kinase inhibitor. (S)-LY3177833 hydrate shows broad in vitro anticancer activity. (S)-LY3177833 hydrate Chemical Structure
  99. GC69914 (S)-Malic acid-d3

    (S)-Malic acid-d3 is the deuterated form of (S)-Malic acid. (S)-Malic acid ((S)-2-Hydroxysuccinic acid) is a naturally occurring dicarboxylic acid and a source of fruity sour taste, commonly used as a food additive.

     (S)-Malic acid-d3 Chemical Structure
  100. GC67989 (S)-Mirtazapine (S)-Mirtazapine Chemical Structure
  101. GC68410 (S)-Mirtazapine-d3 (S)-Mirtazapine-d3 Chemical Structure

Items 201 to 300 of 10000 total

per page
  2. 1
  3. 2
  4. 3
  5. 4
  6. 5

Set Descending Direction